All In Biotech

Drug Trial Radar · NCT03402659

Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease

A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Oct 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 161 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

161

Actual

Start

Dec 29, 2017

Primary completion

Jun 30, 2019

Study completion Jul 31, 2019

Sponsor

Lead sponsor
EIP Pharma IncIndustry
Sponsor type
Industry
Collaborators
Worldwide Clinical Trials; Amsterdam UMC, location VUmc
First posted
Jan 18, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2b, double-blind, placebo controlled proof-of-concept study of a an oral small molecule selective inhibitor of p38 alpha kinase, neflamapimod, administered for 24 weeks in subjects with mild Alzheimer's disease. The primary objective is to demonstrate significant improvement relative to placebo-treatment in episodic memory function, as assessed by the Hopkins Verbal Learning Test. Secondary endpoints include Clinical Dementia Rating scale (CDR), Wechsler Memory Scale (WMS), Mini-Mental-Status-Examination (MMSE) and Cerebrospinal fluid (CSF) biomarkers of AD disease activity and progression.

Conditions

  • Alzheimer Disease

Interventions

  • neflamapimodDrug

    40 mg neflamapimod capsule

  • placeboOther

    matching placebo capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total and Delayed Recall on the Hopkins Verbal Learning Test - Revised (HVLT-R)Time frame: Baseline and 24 weeks

Locations

38 sites in 5 countries. Site status is shown where the registry gives one.

  • Alliance for Research

    Long Beach, California

  • Pacific Research Network

    San Diego, California

  • CITrials

    Santa Ana, California

  • Southern California Research, LLC

    Simi Valley, California

  • Viking Clinical Research

    Temecula, California

  • Miami Dade Medical Research Institute

    Miami, Florida

  • Sensible Healthcare, LLC

    Ocoee, Florida

  • Anchor Neuroscience

    Pensacola, Florida

  • Progressive Medical Research

    Port Orange, Florida

  • Suncoast Neuroscience Associates, Inc.

    St. Petersburg, Florida

  • Florida Premier Research Institute

    Winter Park, Florida

  • Northwest Clinical Trials

    Boise, Idaho

  • MassGeneral Institute for Neurodegenerative Disease

    Charlestown, Massachusetts

  • Manhattan Behavioral Medicine

    New York, New York

  • Alzheimer's Memory Center and Research Institute

    Charlotte, North Carolina

  • Northwest Clinical Research Center

    Seattle, Washington

  • Neuro HK, s.r.o. POLIKLINIKA CHOCEŇ, a.s.

    Choceň, Czechia

  • Cerebrovaskulární poradna s.r.o.

    Moravská Ostrava, Czechia

  • Clintrial S.R.O

    Prague, Czechia

  • Private Psychiatric Centre

    Prague, Czechia

  • Vestra Clinics S.R.O

    Rychnov nad Kněžnou, Czechia

  • CCBR Clinical Research, Aalborg

    Aalborg, Denmark

  • CCBR Clinical Research, Ballerup

    Ballerup Municipality, Denmark

  • CCBR Clinical Research, Vejle

    Vejle, Denmark

  • Jeroen Bosch Ziekenhuis

    's-Hertogenbosch, Netherlands

  • Alzheimer Research Center

    Amsterdam, Netherlands

  • Amphia Ziekhuis

    Breda, Netherlands

  • MAC Clinical Research Tankersley

    Barnsley, United Kingdom

  • Re:Cognition Health Birmingham

    Birmingham, United Kingdom

  • MAC Clinical Research Blackpool

    Blackpool, United Kingdom

  • Fulbourn Hospital

    Cambridge, United Kingdom

  • MAC Clinical Research Leeds

    Leeds, United Kingdom

  • MAC Clinical Research Liverpool

    Liverpool, United Kingdom

  • Re:Cognition Health London

    London, United Kingdom

  • St. Pancras Clinical Research

    London, United Kingdom

  • MAC Clinical Research Manchester

    Manchester, United Kingdom

  • Re:Cognition Health Plymouth

    Plymouth, United Kingdom

  • 5 Boroughs/North West Boroughs Healthcare NHS Foundation Trust

    Warrington, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.